Marcello Tucci

List of Publications by Year
in descending order

51 papers	1,512 citations	331538 21 h-index	315616 38 g-index
51 all docs	51 docs citations	51 times ranked	2770 citing authors

#	Article	IF	Citations
1	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
2	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treatment Reviews, 2015, 41, 884-892.	3.4	141
3	Papillary renal cell carcinoma: A review of the current therapeutic landscape. Critical Reviews in Oncology/Hematology, 2015, 96, 100-112.	2.0	104
4	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 563-573.	0.9	101
5	Chromogranin A Expression in Patients With Hormone NaÃ¯ve Prostate Cancer Predicts the Development of Hormone Refractory Disease. Journal of Urology, 2007, 178, 838-843.	0.2	86
6	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. European Urology, 2015, 68, 147-153.	0.9	73
7	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Network Open, 2020, 3, e2021692.	2.8	70
8	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	5.1	61
9	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. OncoTargets and Therapy, 2018, Volume 11, 7353-7368.	1.0	58
10	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treatment Reviews, 2016, 44, 61-73.	3.4	56
11	Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget, 2015, 6, 12520-12528.	0.8	47
12	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treatment Reviews, 2017, 54, 1-9.	3.4	44
13	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treatment Reviews, 2018, 70, 67-74.	3.4	41
14	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. Critical Reviews in Oncology/Hematology, 2021, 157, 103185.	2.0	41
15	Metastatic castration-resistant prostate cancer: time for innovation. Future Oncology, 2015, 11, 91-106.	1.1	32
16	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clinical Genitourinary Cancer, 2018, 16, e945-e951.	0.9	30
17	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Clinical Genitourinary Cancer, 2019, 17, 291-298.	0.9	30
18	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Cancer Treatment Reviews, 2019, 74, 35-42.	3.4	30

#	Article	IF	Citations
19	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e223-e231.	0.9	27
20	Hormonal treatment and quality of life of prostate cancer patients: new evidence. Minerva Urology and Nephrology, 2018, 70, 144-151.	1.3	25
21	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta OncolÃ³gica, 2017, 56, 555-562.	0.8	24
22	Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. Oncotarget, 2016, 7, 14394-14404.	0.8	23
23	Androgen deprivation modulates gene expression profile along prostate cancer progression. Human Pathology, 2016, 56, 81-88.	1.1	20
24	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treatment Reviews, 2018, 69, 215-223.	3.4	19
25	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 129, 124-132.	2.0	18
26	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987772.	1.4	16
27	Prostate cancer management at an Italian tertiary referral center: does multidisciplinary team meeting influence diagnostic and therapeutic decision-making process? A snapshot of the everyday clinical practice. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 576-582.	3.9	16
28	Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. Cancers, 2021, 13, 5896.	1.7	15
29	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocrine-Related Cancer, 2018, 25, R1-R9.	1.6	13
30	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. Critical Reviews in Oncology/Hematology, 2020, 152, 102994.	2.0	13
31	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. BioMed Research International, 2017, 2017, 1-13.	0.9	10
32	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. Clinical Genitourinary Cancer, 2019, 17, 332-347.e2.	0.9	9
33	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncology, 2016, 12, 493-502.	1.1	8
34	Clinical outcomes in a contemporary series of â€œyoungâ€•patients with castration-resistant prostate cancer who were 60 years and younger. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 265.e15-265.e21.	0.8	6
35	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6
36	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 737-745.	3.9	6

#	Article	IF	Citations
37	Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer and Prostatic Diseases, 2021, 24, 812-825.	2.0	5
38	New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?. Critical Reviews in Oncology/Hematology, 2022, 174, 103682.	2.0	5
39	Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review. Clinical Genitourinary Cancer, 2018, 16, e1087-e1090.	0.9	4
40	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. Clinical Genitourinary Cancer, 2018, 16, 318-324.	0.9	4
41	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Minerva Urology and Nephrology, 2022, 73, .	1.3	4
42	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. Anticancer Research, 2022, 42, 165-172.	0.5	4
43	An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. Minerva Urology and Nephrology, 2017, 69, 349-358.	1.3	3
44	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. Journal of Clinical Oncology, 2019, 37, 219-219.	0.8	3
45	Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?. Minerva Urology and Nephrology, 2022, 73, 870-872.	1.3	3
46	Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study. Minerva Urology and Nephrology, 2022, , .	1.3	2
47	Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias?. Journal of Clinical Oncology, 2017, 35, 1264-1264.	0.8	1
48	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. Journal of Clinical Oncology, 2019, 37, e16013-e16013.	0.8	1
49	Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. Tumori, 2022, , 030089162210771.	0.6	1
50	Zoledronic Acid Dosing Interval for Metastatic Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1477.	3.8	0
51	FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report. BMC Cancer, 2018, 18, 470.	1.1	0